Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial
Rina Hui, Edward B. Garon, J.W. Goldman et al. · Annals of Oncology · 2017
Cited by 237 works. doi:10.1093/annonc/mdx008 Open-access PDF
Authors
- Rina Hui
- Edward B. Garon
- J.W. Goldman
- Natasha B. Leighl
- Matthew David Hellmann
- Amita Patnaik
- Leena Gandhi
- Joseph P. Eder
- Myung‐Ju Ahn
- Leora Horn
- Enriqueta Felip
- Enric Carcereny
- Reshma A. Rangwala
- Gregory M. Lubiniecki
- J. Zhang
- Kenneth Emancipator
- Charlotte M. Roach
- Naiyer A. Rizvi
References
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
- COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial